SID 24785302
SID 24785302 is a hexokinase inhibitor with antiparasitic activity. SID 24785302 exhibits activity against T. brucei and Leishmania. SID 24785302 can be used for the research of mitochondrial DNA disorders and parasitic infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 378197-09-2
- Formule: C14H12N2O3S2
- Masse moléculaire:320.39
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
Description
In Vitro
SID 24785302 (10 μM; 2 h) potently and selectively inhibits bacterially expressed Trypanosoma brucei hexokinase 1 with an IC50 of 4.2 μM, while causing minimal inhibition of human glucokinase at 10 μM[3].
SID 24785302 (3 days) potently inhibits the growth of Trypanosoma brucei bloodstream form parasites with an EC50 of 0.042 μM[3].
SID 24785302 (10 μM; 2 days) moderately inhibits the growth of Trypanosoma brucei procyclic form parasites, causing 47% inhibition at 10 μM[3].
SID 24785302 (44 h) inhibits the growth of Leishmania major promastigotes with an EC50 of 1.9 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 378197-09-2
-
Masse moléculaire 320.39
-
Formule C14H12N2O3S2
-
SMILES
O=C(CC1=CSC(N2SC3=C(C2=O)C=CC=C3)=N1)OCC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
[1]. Antonella SPINAZZOLA, et al. Compounds for treating mitochondrial dna disorders. WO2023089313A1.
[2]. Heneberg P. Redox Regulation of Hexokinases. Antioxid Redox Signal. 2019 Jan 20;30(3):415-442. [Content Brief]
[3]. Sharlow ER, et al. A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis. 2010;4(4):e659. Published 2010 Apr 13. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SID 24785302 Related Classifications
HY-169728 Related Classifications
Powered by Bioz
Keywords
- SID 24785302
- 378197-09-2
- SID24785302
- SID-24785302
- Hexokinase
- Parasite
- mitochondrial DNA disorders
- hexokinase inhibitor
- T. brucei blood stage parasites
- Trypanosoma brucei procyclic form (29-13)
- CYP2D6
- Trypanosoma brucei bloodstream form (90-13)
- Leishmania promastigotes
- Trypanosoma brucei hexokinase 1
- human african trypanosomiasis
- Leishmania major promastigotes
- Inhibitor
- inhibitor
- inhibit